Click aici pentru detalii

Circulation 1997; 96: 1888-92.
[107] Andresen D, Steinbeck G, Bruggemann T et al. Risk
stratification following myocardial infarction in the thrombolytic era:
a two-step strategy using noninvasive and invasive methods. J Am Coll
Cardiol 1999; 33: 131-8.
[108] Hohnloser SH, Franck P, Klingenheben T, Zabel M, Just H.
Open infarct artery, late potentials, and other prognostic factors in
patients after acute myocardial infarction in the thrombolytic era. A
prospective trial. Circulation 1994; 90: 1747-56.
[109] de Chillou C, Sadoul N, Bizeau O et al. Prognostic value
of thrombolysis, coronary artery patency, signal-averaged
electrocardiography, left ventricular ejection fraction, and Holter
electrocardiographic monitoring for life-threatening ventricular
arrhythmias after a first acute myocardial infarction. Am J Cardiol
1997; 80: 852-8.
[110] Comparison of invasive and conservative strategies after
treatment with intravenous tissue plasminogen activator in acute
myocardial infarction. Results of the thrombolysis in myocardial
infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J
Med 1989; 320: 618-27.
[111] Michels KB, Yusuf S. Does PTCA in acute myocardial
infarction affect mortality and reinfarction rates? A quantitative
overview (meta-analysis) of the randomized clinical trials. Circulation
1995; 91: 476-85.
[112] Acute myocardial infarction: pre-hospital and in-hospital
management. The Task Force on the Management of Acute
Myocardial Infarction of the European Society of Cardiology. Eur
Heart J 1996; 17: 43-63.
[113] Indications for ACE inhibitors in the early treatment of acute
myocardial infarction: systematic overview of individual data from
100,000 patients in randomized trials. ACE Inhibitor Myocardial
Infarction Collaborative Group. Circulation 1998; 97: 2202-12.
[114] Ziesche S, Rector ST, Cohn JN. Interobserver discordance in
the classification of mechanisms of death in studies of heartfailure. J
Card Fail 1995; 1: 127-32.
[115] Cohn JN, Johnson G, Ziesche S et al. A comparison of
enalapril with hydralazine-isosorbide dinitrate in the treatment of
chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
[116] Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure. The SOLVD
Investigators. N Engl J Med 1991; 325: 293-302.
[117] Hennekens CH, Albert CM, Godfried SL, Gaziano JM,
Buring JE. Adjunctive drug therapy of acute myocardial infarctionevidence
from clinical trials. N Engl J Med 1996; 335: 1660-7.
[118] Domanski MJ, Exner DV, Borkowf CB, Geller NL,
Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme
inhibition on sudden cardiac death in patients following acute
myocardial infarction. A meta-analysis of randomized clinical trials. J
Am Coll Cardiol 1999; 33: 598-604.
[119] Pitt B, Zannad F, Remme WJ. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N Engl J Med
1999; 341: 709-17.
[120] LaRosa JC, He J, Vupputuri S. Effect of statins on risk of
coronary disease. A meta-analysis of randomized controlled trials.
JAMA 1999; 282: 2340-6.
[121] Dietary supplementation with n-3 polyunsaturated fatty acids
and vitamin E after myocardial infarction: results of the GISSI-
Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto miocardico. Lancet 1999; 354: 447-55.
[122] Indications for fibrinolytic therapy in suspected acute
myocardial infarction: collaborative overview of early mortality and
major morbidity results from all randomised trials of more than 1000
patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.
Lancet 1994; 343: 311-22.
[123] Randomised trial of intravenous streptokinase, oral aspirin,
63
both, or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. ISIS-2 (Second International Study of Infarct
Survival) Collaborative Group. Lancet 1988; 2: 349-60.
[124] Topol EJ, Mark DB, Linco. AM et al. Outcomes at 1 year and
economic implications of platelet glycoprotein IIb/IIIa blockade in
patients undergoing coronary stenting: results from a multicentre
randomised trial. EPISTENT Investigators. Evaluation of Platelet
IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-24.
[125] Anand SS, Yusuf S. Oral anticoagulant therapy in patients with
coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058-67.
[126] Collins R, MacMahon S, Flather M et al. Clinical effects of
anticoagulant therapy in suspected acute myocardial infarction:
systematic overview of randomised trials. BMJ 1996; 313: 652-9.
[127] Weaver WD, Simes RJ, Betriu A et al. Comparison of primary
coronary angioplasty and intravenous thrombolytic therapy for acute
myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-8.
[128] Ambrosioni E, Borghi C, Magnani B. The effect of the
angiotensin-converting-enzyme inhibitor zofenopril on mortality and
morbidity after anterior myocardial infarction. The Survival of
Myocardial Infarction Long-Term Evaluation (SMILE) Study
Investigators. N Engl J Med 1995; 332: 80-5.
[129] Flather MD, Yusuf S, Kober L et al. Long-term ACE inhibitor
therapy in patients with heart failure or left ventricular dysfunction: a
systematic overview of data from individual patients. Lancet 2000;
355: 1575-81.
[130] Effect of ramipril on mortality and morbidity of survivors of
acute myocardial infarction with clinical evidence of heart failure. The
Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet
1993; 342: 821-8.
[131] Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of
the angiotensin-converting-enzyme inhibitor trandolapril in patients
with left ventricular dysfunction after myocardial infarction.
Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J
Med 1995; 333: 1670-6.
[132] Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril
on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction. Results of the survival and
ventricular enlargement trial. The SAVE Investigators. N Engl J Med
1992; 327: 669-77.
[133] ISIS-4: a randomised factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium sulphate in
58.050 patients with suspected acute myocardial infarction. ISIS-4
(Fourth International Study of Infarc Survival) Collaborative Group.
Lancet 1995; 345: 669-85.
[134] GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate
singly and together on 6-week mortality and ventricular function after
acute myocardial infarction. Gruppo Italiano per lo Studio della
Sopravvivenza nell’infarto Miocardico. Lancet 1994; 343: 1115-22.
[135] Effect of enalapril on mortality and the development of heart
failure in asymptomatic patients with reduced left ventricular ejection
fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-91.
[136] Effects of enalapril on mortality in severe congestive heart
failure. Results of the Cooperative North Scandinavian Enalapril
Survival Study (CONSENSUS). The CONSENSUS Trial Study
Group. N Engl J Med 1987; 316: 1429-35.
[137] Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of
excessive extracellular matrix turnover may contribute to survival
benefit of spironolactone therapy in patients with congestive heart
failure: insights from the Randomized Aldactone Evaluation Study
(RALES). Circulation 2000; 102: 2700-6.
[138] Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival Study
(4S). Lancet 1994; 344: 1383-9.
[139] Sacks FM, Pfeffer MA, Moye LA et al. The effect of
pravastatin on coronary events after myocardial infarction in patients
with average cholesterol levels. Cholesterol and Recurrent Events Trial
REVISTA ROMÅN~ DE CARDIOLOGIE Vol. XIX, Nr. 1, An 2004